HIV News and Research RSS Feed - HIV News and Research

Sofosbuvir-based regimens effective in HIV-HCV co-infected, cirrhotic patients

Sofosbuvir-based regimens effective in HIV-HCV co-infected, cirrhotic patients

A new study revealed today at The International Liver Congress 2015 shows that sofosbuvir (SOF)-based regimens are effective and well tolerated in hepatitis C and HIV co-infected, cirrhotic patients. Sustained virologic response at 4 weeks (SVR4) was observed in 98% of patients and in 95% at 12 weeks (SVR12). [More]
New Cannabis and Cannabinoid Research journal to be launched in fall 2015

New Cannabis and Cannabinoid Research journal to be launched in fall 2015

Cannabis and Cannabinoid Research, a new peer-reviewed, open access journal from Mary Ann Liebert, Inc., publishers, is the only journal dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the biochemical mechanisms of endocannabinoids. [More]
Systematic review shows hepatitis B and C testing lacking in many European countries

Systematic review shows hepatitis B and C testing lacking in many European countries

The apparent dearth of research on hepatitis B and C testing in many European countries could be hampering efforts to identify infected individuals, according to results from a comprehensive review of 136 studies presented today at The International Liver Congress 2015. [More]
AUDs have negative prognostic outcome with higher mortality risks in patients with HCV infection

AUDs have negative prognostic outcome with higher mortality risks in patients with HCV infection

Results presented today at The International Liver Congress 2015, show that alcohol use disorders (AUD) have a serious, negative prognostic outcome with higher mortality risks in the general population and patients with hepatitis C virus (HCV) infection in particular. [More]
AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV). [More]
Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

Enrollment begins for first major cardiovascular prevention trial for people infected with HIV

The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at Massachusetts General Hospital, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand with funding from the National Heart, Lung, and Blood Institute in collaboration with the AIDS Clinical Trials Group and support from the National Institutes of Allergy and Infectious Diseases. [More]
Findings suggest development of 'post-infection' vaccine to reduce TB rates in China

Findings suggest development of 'post-infection' vaccine to reduce TB rates in China

A major contributor to the number of tuberculosis infections and cases in China will likely be the elderly over the next few decades, requiring a refocus in efforts to control a disease affecting millions of people in the country, according to preliminary new research presented today at the Fourth Global Forum on TB Vaccines in Shanghai. [More]
WHO calls on global health community to address significant gaps in prevention, treatment of malaria

WHO calls on global health community to address significant gaps in prevention, treatment of malaria

WHO is calling on the global health community to urgently address significant gaps in the prevention, diagnosis and treatment of malaria. Despite dramatic declines in malaria cases and deaths since 2000, more than half a million lives are still lost to this preventable disease each year. [More]

Daclatasvir-sofosbuvir treatment highly effective in patients with HCV and HIV co-infection

Phase III results revealed today at The International Liver Congress 2015 show that once-daily treatment with daclatasvir (DCV) plus sofosbuvir (SOF) resulted in an overall 97% sustained virologic response (SVR) at 12 weeks post-treatment in patients with hepatitis C virus (HCV) and HIV co-infection, including cirrhotic patients. [More]
Mylan introduces generic Sofosbuvir 400 mg tablets in India under brand name MyHep

Mylan introduces generic Sofosbuvir 400 mg tablets in India under brand name MyHep

Mylan N.V. today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched generic Sofosbuvir 400 mg tablets under the brand name MyHep in India. [More]
Ebola survivors face long-term adverse health effects: Study

Ebola survivors face long-term adverse health effects: Study

Ebola survivors experienced negative health effects that persisted more than two years after the 2007-2008 Bundibugyo ebolavirus (BDBV) outbreak in Uganda that claimed 39 lives. These findings are detailed in a paper published online today in Lancet ID. [More]
Study finds increasing size of elderly population as major contributor to TB infection in China

Study finds increasing size of elderly population as major contributor to TB infection in China

A major contributor to the number of tuberculosis infections and cases in China will likely be the elderly over the next few decades, requiring a refocus in efforts to control a disease affecting millions of people in the country, according to preliminary new research presented today at the Fourth Global Forum on TB Vaccines in Shanghai. [More]

Bars, street corners ideal for broad dissemination of HIV prevention information among at-risk individuals

Bars and street corners are ideal venues for broad dissemination of HIV prevention information among drug-using male sex workers and other at-risk populations, according to researchers from The University of Texas Health Science Center at Houston. [More]
Study calls for effective strategies to contain potential HDV epidemic in high-risk populations

Study calls for effective strategies to contain potential HDV epidemic in high-risk populations

Researchers from Taiwan determined that individuals with human immunodeficiency virus (HIV) infection or those who inject illicit drugs have a higher risk of becoming infected with the hepatitis D virus (HDV) in that country. [More]
French clinicians diagnose first case of rabies since 2003

French clinicians diagnose first case of rabies since 2003

A team of French clinicians has diagnosed the first case of rabies in that country since 2003. Only 20 cases of human rabies had been diagnosed in France between 1970 and 2003. Moreover, the patient was unaware of having been bitten. [More]
Miriam Hospital awarded BDC designation for bariatric surgery

Miriam Hospital awarded BDC designation for bariatric surgery

Blue Cross Blue Shield of Rhode Island has awarded The Miriam Hospital a Blue Distinction Center+ (BDC) designation for bariatric surgery. A designation by the Blue Distinction Centers for Specialty Care program, BDCs are nationally designated health care facilities that deliver quality specialty care based on objective measures for patient safety and better health outcomes. [More]

Bio-Rad grants Beckman Coulter exclusive distribution rights for access HIV and Hepatitis C assays

Bio-Rad is extending its agreement with Beckman Coulter and has named the company exclusive global distributor of Bio-Rad’s Access HIV combo assay and the Access hepatitis C virus (HCV) assay in select geographies... [More]
UCLA-led stroke study selected as one of 10 most outstanding research papers by CRF

UCLA-led stroke study selected as one of 10 most outstanding research papers by CRF

A UCLA-led study on improving stroke care was selected by the Clinical Research Forum (CRF) as one of the 10 most outstanding research papers written by teams from across the nation in 2014. The organization highlighted the papers at its fourth annual awards ceremony in Washington, D.C. on April 16. [More]
UC San Diego study examines counterfeit drug penetration in global medicine supply chains

UC San Diego study examines counterfeit drug penetration in global medicine supply chains

When you take a medication for, say, high cholesterol, do you know that pill is really what the label says it is? Depending upon the type of medicine and where you live, the threat of falsified medications (also referred to as counterfeit, fraudulent, and substandard) can be quite real, yet the full scope and prevalence of the problem is poorly understood, say researchers at University of California, San Diego School of Medicine in a new report published April 20 in the American Journal of Tropical Medicine and Hygiene. [More]
Mott poll measures public's views about use of medical marijuana for children

Mott poll measures public's views about use of medical marijuana for children

Medical marijuana and children don't mix, most Americans say. While nearly two-thirds of people agree that their state should allow medical marijuana for adults, half as many - just over a third - say it should be allowed for children, according to today's University of Michigan C.S. Mott Children's Hospital National Poll on Children's Health that included a national sample of adults in the U.S. [More]
Advertisement